European regulators published a joint clinical assessment for the breast cancer treatment Camizestrant, known commercially as Etcamah, following its authorization across the European Union on July 20, agenceurope.eu reported.
European Health Authorities Review Breast Cancer Drug
The European Commission released the evaluation on November 6, as agenceurope.eu reported. The assessment covers a targeted therapy designed for patients diagnosed with locally advanced or metastatic breast cancer carrying an ESR1 gene mutation.
Austria and Belgium conducted the evaluation under the European Union health technology assessment regulation. Member states approved the report on August 19 to help guide national treatment decisions and reimbursement policies.
Camizestrant Offers Therapeutic Options for EU Breast Cancer Patients
Nearly 375,000 women received a breast cancer diagnosis across the European Union in 2022, while 96,000 died from the disease, according to the official document cited by agenceurope.eu. Camizestrant offers a specific therapeutic option for tumors characterized by estrogen receptor 1 alterations.
National health authorities across member states will use this joint clinical assessment to determine how the medicine enters domestic markets and public reimbursement systems. Additional joint reports covering other pharmaceutical products are scheduled for publication in the coming months.
Camizestrant Targets Advanced Breast Cancer with ESR1 Mutations
- Targeted Population: The assessment evaluates Camizestrant specifically for patients with advanced breast cancer harboring an ESR1 gene mutation.
- Regulatory Framework: The evaluation operates under the European Union health technology assessment framework to streamline cross-border clinical reviews.
- National Access: Member states use the shared findings to shape local healthcare coverage and reimbursement policies.
| Metric | Data Point |
|---|---|
| EU Breast Cancer Diagnoses (2022) | ~375,000 |
| EU Breast Cancer Deaths (2022) | 96,000 |
| Drug Authorization Date | July 20 |
| Assessment Approval Date | August 19 |
References
- Agence Europe. Joint clinical assessment report on Camizestrant (Etcamah). https://aeur.eu/f/obn
